Approval · Notice of Compliance 20245 · 2018
COMPONENT E-S IMPLANTS WITH TYLAN: Notice of Compliance 20245
Issued January 8, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 20245
- Date
- January 8, 2018
- Company
- Elanco Division Eli Lilly Canada IncGuelph, Ontario, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- CHANGE TO A PRESCRIPTIOM STATUS. lABELLING UPDATES
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COMPONENT E-S IMPLANTS WITH TYLAN | 02245743 | Marketed |
Medicinal ingredients
- ESTRADIOL BENZOATE 20 MG per IMP
- PROGESTERONE 200 MG per IMP
- TYLOSIN TARTRATE 29 MG per IMP